DIAGNOS Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

DIAGNOS wird voraussichtlich einen Umsatzanstieg von 229.9% pro Jahr verzeichnen. Der Gewinn pro Aktie wird voraussichtlich wachsen.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

57.2%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	27.0%
Wachstumsrate der Einnahmen	229.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

DIAGNOS Inc.'s (CVE:ADK) Profit Outlook

Apr 29

Recent updates

DIAGNOS Inc.'s (CVE:ADK) Profit Outlook

Apr 29

Gewinn- und Umsatzwachstumsprognosen

TSXV:ADK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2025	6	N/A	N/A	N/A	1
3/31/2024	0	N/A	N/A	N/A	1
12/31/2023	0	-3	-2	-2	N/A
9/30/2023	0	-3	-2	-2	N/A
6/30/2023	0	-3	-2	-2	N/A
3/31/2023	0	-2	-2	-2	N/A
12/31/2022	1	-2	-2	-2	N/A
9/30/2022	1	-3	-2	-2	N/A
6/30/2022	1	-3	-2	-2	N/A
3/31/2022	0	-3	-2	-2	N/A
12/31/2021	0	-3	-2	-2	N/A
9/30/2021	0	-2	-2	-2	N/A
6/30/2021	0	-2	-2	-2	N/A
3/31/2021	0	-2	-1	-1	N/A
12/31/2020	0	-3	-2	-2	N/A
9/30/2020	0	-3	-2	-2	N/A
6/30/2020	0	-3	-2	-2	N/A
3/31/2020	0	-3	-3	-3	N/A
12/31/2019	0	-3	-2	-2	N/A
9/30/2019	0	-3	-2	-2	N/A
6/30/2019	0	-4	-3	-3	N/A
3/31/2019	0	-4	-2	-2	N/A
12/31/2018	0	-4	-3	-3	N/A
9/30/2018	1	-4	-2	-2	N/A
6/30/2018	1	-3	-2	-1	N/A
3/31/2018	1	-4	-3	-2	N/A
12/31/2017	2	-4	-2	-2	N/A
9/30/2017	2	-3	N/A	-2	N/A
6/30/2017	2	-4	N/A	-2	N/A
3/31/2017	2	-3	N/A	-2	N/A
12/31/2016	1	-2	N/A	-1	N/A
9/30/2016	0	-3	N/A	-2	N/A
6/30/2016	1	-3	N/A	-2	N/A
3/31/2016	1	-3	N/A	-2	N/A
12/31/2015	1	-3	N/A	-2	N/A
9/30/2015	1	-3	N/A	-2	N/A
6/30/2015	1	-3	N/A	-2	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-3	N/A	-3	N/A
9/30/2014	1	-2	N/A	-2	N/A
6/30/2014	2	-2	N/A	-1	N/A
3/31/2014	3	-2	N/A	-1	N/A
12/31/2013	3	-1	N/A	-1	N/A
9/30/2013	3	-1	N/A	-2	N/A
6/30/2013	2	-2	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von ADK über der Sparquote liegt (2.1%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von ADK schneller wachsen werden als der Markt Canadian

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ADK in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: ADKDie Einnahmen des Unternehmens (229.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (7.3% pro Jahr).

Hohe Wachstumseinnahmen: ADKDie Einnahmen des Unternehmens (229.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ADK in 3 Jahren voraussichtlich hoch sein wird

DIAGNOS Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 50% to CA$1.50

Price target decreased to CA$1.00

Price target decreased to CA$1.00

Price target increased to CA$1.55

DIAGNOS Inc.'s (CVE:ADK) Profit Outlook

Recent updates

DIAGNOS Inc. announced that it has received CAD 1.295821 million in funding

DIAGNOS Inc. announced that it expects to receive CAD 1.5 million in funding

Diagnos Inc. Announces to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024

DIAGNOS Inc. to Expedite Application for Medical Device License to Health Canada and US FDA Related to its 4 New Analysis Modules, and is Planning ISO 27001 Certification

Less than half of directors are independent

DIAGNOS Inc. Appoints Philippe Couillard to Its Board of Directors

DIAGNOS Inc. announced that it has received CAD 0.578 million in funding

DIAGNOS Inc. Appoints Michael Braeuel to Board of Directors

New major risk - Financial position

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Insider recently sold CA$240k worth of stock

Diagnos Inc. Appoints Yves-Stéphane Couture as Chief Operating Officer

Diagnos Inc. Announces the Appointment of Yves-Stéphane Couture as Chief Operating Officer

Price target increased by 50% to CA$1.50

DIAGNOS Inc. announced that it has received CAD 0.640051 million in funding

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.01 loss in 1Q 2023)

DIAGNOS Inc., Annual General Meeting, Sep 28, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

DIAGNOS Inc. announced that it has received CAD 0.865 million in funding

DIAGNOS and ETS to Present Research on Mass Screening for Macular Edema at ARVO 2023

Diagnos Inc Gets the Green Light for the Use of Its Diabetic Retinopathy Screening Technology in Quebec Hospitals

Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in 3Q 2022)

DIAGNOS Inc. announced that it has received CAD 0.25 million in funding

DIAGNOS Inc. announced that it has received CAD 0.85 million in funding

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in 2Q 2022)

DIAGNOS Inc. announced that it has received CAD 0.5 million in funding

Price target decreased to CA$1.00

DIAGNOS Inc. announced that it has received CAD 0.35 million in funding

DIAGNOS Inc. announced that it has received CAD 0.35 million in funding

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

DIAGNOS Inc. Receives Regulatory Approval from the Costa Rica Health Agency for Its Artificial Intelligence Enabled Pathology Detection Systems

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to CA$1.00

DIAGNOS Inc., Annual General Meeting, Aug 25, 2022

DIAGNOS Inc. Announces the Deployment of its Age-Related Macular Degeneration Detection Application Into the Optometry Clinics of IRIS, The Visual Group

Price target increased to CA$1.55

DIAGNOS Inc. announced that it has received CAD 0.93 million in funding

DIAGNOS Inc. announced that it has received CAD 0.59 million in funding

Insider recently sold CA$88k worth of stock

Independent Director recently bought CA$52k worth of stock

Diagnos Inc. Announces the Beginning of A Clinical Trial Study with CommonSpirit Health Research Institute, Chattanooga Center

Second quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.006 loss in 2Q 2021)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

First quarter 2022 earnings released: CA$0.011 loss per share (vs CA$0.008 loss in 1Q 2021)

Insider recently bought CA$51k worth of stock

Full year 2021 earnings released: CA$0.033 loss per share (vs CA$0.083 loss in FY 2020)

Insider recently bought CA$54k worth of stock

DIAGNOS Inc.'s (CVE:ADK) Profit Outlook

Diagnos Inc. Announces the Final Step of the Development of Its Stroke Predictor (Cara-St) Based on Images of the Retina

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken